



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代碼：02607)

NOTIFICATION LETTER 通知信函

19 September 2023

Dear Shareholder,

Shanghai Pharmaceuticals Holding Co., Ltd.* (the "Company") – Notice of Publication of 2023 Interim Report ("Current Corporate Communication")

The English and Chinese versions of the Current Corporate Communication are available on, and may be accessed under "Financial Report" in the Investor Relations section of the Company's website at www.sphchina.com and are also available on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk. If you have elected to receive corporate communications[#] in printed form, the printed form (or forms) of the Current Corporate Communication is (or are) enclosed.

If you would like (i) to receive future corporate communications from the Company in printed form instead of in electronic form on the Company's website (or in electronic form on the Company's website instead of in printed form) or (ii) to change the language in which you receive corporate communications in printed form, please complete the Change Request Form on the reverse side of this letter and sign and return it by post or by hand to the Company c/o the Company's H share registrar in Hong Kong (the "H Share Registrar"), Link Market Services (Hong Kong) Pty Limited, at Suite 1601, 16/F, Central Tower, 28 Queen's Road Central, Hong Kong. If you post your reply in Hong Kong, you may use the mailing label in the Change Request Form and need not affix a stamp on the envelope when returning your Change Request Form. Otherwise, please affix an appropriate stamp. You may also send an email with a scanned copy of the completed Change Request Form to hkenquiries@linkmarketservices.com. The Change Request Form may also be downloaded from the Company's website at www.sphchina.com or the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

If you have elected (or are deemed to have elected) to receive the Current Corporate Communication in electronic form on the Company's website and for any reason have difficulty in obtaining access to corporate communications on the Company's website, the Company will upon request send the Current Corporate Communication to you in printed form free of charge.

You may at any time by reasonable notice in writing to the Company (sent to the H Share Registrar at the above address or by email to hkenquiries@linkmarketservices.com) elect (i) to receive future corporate communications from the Company in printed form instead of in electronic form on the Company's website (or in electronic form on the Company's website instead of in printed form) or (ii) to change the language in which you receive corporate communications in printed form.

Should you have any questions in relation to this letter, please call the telephone hotline of the H Share Registrar at (852) 3707 2600 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHOU Jun
Chairman

* For identification purpose only

Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and accounts contained in them), notices of meetings, listing documents, circulars, proxy forms and reply slips.

各位股東：

上海醫藥集團股份有限公司（「公司」） – 二零二三年中期報告（「本次公司通訊」）之發佈通知

本次公司通訊之中、英文版本已上載於公司網站（www.sphchina.com）之投資者關係內的「財務報告」網頁及香港聯合交易所有限公司披露易網站（www.hkexnews.hk），歡迎查閱。如閣下已選擇收取公司通訊[#]之印刷本，本次公司通訊之印刷本隨本函附上。

如閣下欲 (i) 收取公司將來的公司通訊之印刷本，以取代於公司網站登載的電子本（或收取於公司網站登載的公司通訊電子本，以取代印刷本）或 (ii) 更改所收取的公司通訊印刷本的語言版本，請閣下填妥在本函背面的變更申請表，並在變更申請表上簽名，然後把變更申請表寄回或親手交回公司之 H 股證券登記處 Link Market Services (Hong Kong) Pty Limited（「H 股證券登記處」），地址為香港皇后大道中 28 號中匯大廈 16 樓 1601 室。倘若閣下在香港投寄，可使用變更申請表內的郵寄標籤寄回，而毋須在信封上貼上郵票；否則，請貼上適當的郵票。閣下亦可把已填妥之變更申請表的掃描副本電郵至 hkenquiries@linkmarketservices.com。變更申請表可於公司網站（www.sphchina.com）或香港聯合交易所有限公司披露易網站（www.hkexnews.hk）內下載。

如閣下已選擇（或被視為已同意）收取於公司網站登載的本次公司通訊電子本，惟因故查閱公司通訊上出現困難，只要閣下提出要求，公司將儘快寄上所要求的本次公司通訊的印刷本，費用全免。

閣下可以隨時透過 H 股證券登記處以書面郵寄至上址或透過電郵至 hkenquiries@linkmarketservices.com 通知公司，選擇 (i) 收取公司將來的公司通訊之印刷本，以取代於公司網站登載的電子本（或收取於公司網站登載的公司通訊電子本，以取代印刷本）或 (ii) 更改所收取的公司通訊印刷本的語言版本。

閣下如有任何與本函內容有關的疑問，請致電 H 股證券登記處電話熱線 (852) 3707 2600，辦公時間為星期一至星期五（公眾假期除外）上午 9 時正至下午 6 時正。

承董事會命
上海醫藥集團股份有限公司
董事長
周軍

二零二三年九月十九日

* 僅供識別

公司通訊乃公司向其證券持有人發出以供參照或採取行動的任何文件，包括但不限於年度和中期財務報告及其摘要報告（及其中包含的所有報告及帳目）、會議通告、上市文件、通函、代表委任表格及回條。

